Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
stockMarket

NR21 Stock Is 10% Down So Far Today

Loading stream...

(vianews) - shares of nr21 (cac 40: nr21.pa) slid 10% to €81.00 at 13:06 est on wednesday, after five sequential sessions in a row of losses. cac 40 is falling 0.97% to €7,237.93, after three consecutive sessions in a row of losses. this seems, up until now, a somewhat negative trend exchanging session today.

about nr21

nr21 société anonyme does not have significant operations. previously, it was involved in design and distribution of underwear and indoor clothing for men, women, and children. the company is based in paris, france.

volatility

nr21's last week, last month's, and last quarter's current intraday variation average was a negative 11.11%, a negative 9.06%, and a positive 6.02%.

nr21's highest amplitude of average volatility was 11.11% (last week), 9.06% (last month), and 6.02% (last quarter).

volume

today's last reported volume for nr21 is 4 which is 300% above its average volume of 1.

more news about nr21 (nr21.pa).

Categories

stockMarket

Tags

Stock PricePrice DownMarket Session NowNR21.PAStock Price DownStock Market NowMarket SessionNR21Stock MarketStock
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com